Your doctor can give you some guidance on handling any metabolic changes, optimizing the benefits of semaglutide GLP-1 treatment, and promoting overall metabolic health
However, the binding of the agonist is greater than that of the natural hormone, GLP-1, and lasts longer
Ongoing research and clinical vigilance are essential to fully understand and manage these potential side effects, ensuring that patients can safely and effectively use semaglutide to improve their health outcomes
Cindy Pocali Shelly Hester Stacy Bohannon We Deliver
Aghwan ZA, Sazili AQ, Alimon AR, et al
For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions
